bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2019: S A J J M A M F J
2018: D N O S

 
  Other news for:
Depression
Epilepsy
Seizures
 Resources from HONselect
Anti-Seizure Drug May Be New Weapon Against Depression

By Steven Reinberg
HealthDay Reporter

THURSDAY, Nov. 1, 2018 (HealthDay News) -- A drug used to control seizures may be a potent weapon against depression in patients who don't find relief with antidepressants, a small pilot study suggests.

Some of the 18 patients taking ezogabine (Potiga) experienced a 45 percent reduction in depression and an increase in their ability to feel pleasure, as well as an increase in resilience and the capacity to recover from extremes of trauma and stress, the researchers reported.

"This drug might be relevant for patients who don't do well with conventional antidepressants," said lead researcher Dr. James Murrough. He is director of the mood and anxiety disorders program at the Icahn School of Medicine at Mount Sinai, in New York City.

Ezogabine was approved in 2011 by the U.S. Food and Drug Administration as an anti-seizure medication. Shortly after its approval, concerns were raised about the drug's effect on the retina and the possibility of it causing blindness.

The FDA ordered the drug's maker, GlaxoSmithKline, to do further safety studies. After reviewing those studies, the FDA ruled in 2015 that the drug did not appear to affect vision. Still, the company withdrew ezogabine from the U.S. market in 2017, citing poor sales.

Even so, psychiatrists noted that if the drug proves effective against depression in larger studies, other drugs that target this area of the brain could be developed.

Some 15 million Americans suffer from major depressive disorder, which is a leading cause of disability. Treatments include selective serotonin reuptake inhibitors (SSRIs) such a Prozac and Paxil, but they are not effective across the board, the researchers noted.

It may be that depression is not one disease, but several that affect different areas of the brain, Murrough said.

That's why new approaches are needed to increase the number of drugs available that target different areas of the brain where depression arises and help patients cope with depression's various forms, he said.

"Ongoing research is trying to find new ways to treat depression based on understanding what's going on in the brain when someone gets depressed and how can we reverse that," Murrough said.

Ezogabine works by increasing the activity of the area in the brain that controls potassium. Murrough explained animal studies have shown that depression can reduce the activity of this potassium channel and that ezogabine can increase its activity, thus relieving depression.

To see if the drug could work in humans, Murrough and his colleagues treated 18 people suffering from major depression with daily doses of ezogabine for 10 weeks.

MRI scans of the participants found that the drug activated the brain's so-called reward system, which resulted in a significant reduction of depressive symptoms.

Not all patients responded to the drug, which might mean that their condition has a different cause, Murrough said.

The researchers said they are currently conducting a larger trial that will compare ezogabine with a placebo, to get a better idea of how effective the drug is at treating depression.

The report was published online Nov. 1 in the journal Molecular Psychiatry.

Dr. Victor Fornari is a psychiatrist at Lenox Hill Hospital in New York City. He said, "We need to find newer ways to treat depression," and ezogabine might be one of these new approaches.

"This study doesn't change treatment -- yet," he added. "At least this is preliminary evidence that this potassium channel target might be another avenue for treatment."

More information

Visit the U.S. National Institute of Mental Health for more on depression.

SOURCES: James Murrough, M.D., Ph.D., director, mood and anxiety disorders program, associate professor, psychiatry and neuroscience, Icahn School of Medicine at Mount Sinai, New York City; Victor Fornari, M.D., psychiatrist, Lenox Hill Hospital, New York City; Nov. 1, 2018, Molecular Psychiatry, online

Copyright © 2018 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=739168

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Depression
Brain
Psychiatry
Affect
Research Personnel
Therapeutics
Potassium
Anxiety Disorders
Seizures
Anxiety
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact